Cantor Fitzgerald maintains Overweight on Kalvista shares

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for sebetralstat, also known as EKTERLY. The stock has shown remarkable momentum, gaining over 47% year-to-date, with analyst targets ranging from $18 to $39. According to InvestingPro data, seven analysts have recently revised their earnings expectations upward for the upcoming period. The webinar, held on March 25, 2025, featured key opinion leaders (KOLs) and outlined the progress of sebetralstat, an oral plasma kallikrein inhibitor developed for on-demand treatment of hereditary angioedema (HAE) attacks.

During the webinar, insights from KOLs highlighted the significance of sebetralstat in the treatment landscape of HAE. Hereditary angioedema is a rare and potentially life-threatening condition characterized by sudden and severe swelling in various parts of the body. Currently, patients rely on injectable treatments to manage acute HAE attacks.

Sebetralstat has been identified as a clinically validated target for both on-demand and prophylactic treatment settings. Cantor Fitzgerald expressed optimism about the drug’s potential, citing its oral administration as a key advantage that could position it to replace injectable treatments as the preferred on-demand therapy for HAE.

The firm’s analyst noted the high likelihood of sebetralstat gaining approval and becoming the first oral treatment for acute HAE attacks that is both effective and safe. This development could mark a significant shift in the management of HAE, offering patients a more convenient treatment option.

Kalvista Pharmaceuticals’ focus on advancing sebetralstat underscores the company’s commitment to addressing the unmet medical needs within the HAE community. While the company maintains a strong liquidity position with a current ratio of 10.44 and more cash than debt, InvestingPro analysis indicates rapid cash burn and negative profit margins require careful monitoring. The Overweight rating from Cantor Fitzgerald reflects a positive outlook on Kalvista’s stock as the company progresses towards potential regulatory approval and commercialization of its novel therapy. With a market capitalization of $621 million and current trading levels suggesting the stock may be overvalued, investors seeking deeper insights can access additional analysis and 8 more exclusive ProTips through InvestingPro’s comprehensive financial health assessment tools.

In other recent news, KalVista Pharmaceuticals has been active with significant developments around its investigational drug, sebetralstat, aimed at treating hereditary angioedema (HAE) attacks. KalVista reported the completion of enrollment for its pediatric KONFIDENT-KID trial, which evaluates sebetralstat in children aged two to 11, making it potentially the first oral on-demand treatment for this demographic. The company anticipates releasing initial results from this trial later this year, with a supplemental New Drug Application submission expected by mid-2026. Furthermore, JMP analysts reiterated a Market Outperform rating for KalVista, projecting U.S. peak sales for sebetralstat at $250 million, with potential revenue projections for upcoming fiscal years surpassing consensus estimates. H.C. Wainwright also maintained a Buy rating, highlighting sebetralstat’s ease of use over existing treatments, and Jefferies adjusted its price target for KalVista to $31, while noting the underappreciated market opportunity for the drug. Additionally, KalVista shared new data showing sebetralstat’s promise in reducing time to relief for HAE attacks, with a median time of 11.5 minutes from attack onset to treatment in the KONFIDENT-S study. The drug is under regulatory review by the U.S. FDA, with a PDUFA goal date set for June 17, 2025, and KalVista has filed regulatory applications in multiple global markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.